Brain-Computer Interface and Augmented Reality for Neurodegenerative Diseases

The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases.

The Cognixion ONE Axon is a prescribed mobile device that can be used by individuals with severe motor and speech disabilities. They can use this wearable device to run applications on the visor where they can see them as holograms, as if you’re looking over the real world with sunglasses, except the graphics are projected into the lens.

The Cognixion ONE is an assisted reality device designed to help patients with neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) as well as acquired conditions that result in severe motor impairments.1 The device uses electroencephalogram (EEG) technology and a noninvasive brain-computer interface for more effective communication in a wearable, augmented reality (AR) headset, designed for patients with advanced disease progression.

In recent news, the device was granted FDA Breakthrough Device designation, aiming to help people with severe motor impairments communicate and interact more with the world around them.1 Currently, there is no approved device that allows fully paralyzed or locked-in patients to communicate once standard of care eye-tracking becomes no longer usable because of ocular motor decline.

Recently, Andreas Forsland, chief executive officer and Founder of Cognixion, sat down with NeurologyLive® in an interview to discuss how the Cognixion ONE Axon will impact healthcare for patients with neurodegenerative diseases like ALS. In addition, he explained the methods that can be used to interact with holographic buttons in the AR display. Forsland also talked about the different applications that are available on the device and how they benefit users, specifically those with severe motor and speech disabilities.

Cognixion Website :


Author: Neurologica

Leave a Reply